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Abstract
Objective:  To  describe  and  analyze  the  occurrence  of  hospitalizations  for  community-acquired
pneumonia  in  children  before  and  after  the  pneumococcal  10-valent  conjugate  vaccine  imple-
mentation into  the  National  Immunization  Program.
Methods:  This  is  an  ecological  study  that  includes  records  of  children  younger  than  one  year
old, vaccinated  and  not  vaccinated  with  the  pneumococcal  10-valent  conjugate  vaccine  in  the
periods pre-  and  post-inclusion  of  the  vaccine  in  the  National  Immunization  Program  in  the
area covered  by  the  Regional  Health  Superintendence  of  Alfenas,  state  of  Minas  Gerais,  Brazil.
Vaccination  was  considered  as  the  exposure  factor  and  hospitalization  for  community-acquired
pneumonia  as  the  endpoint,  using  secondary  annual  data  by  municipality.  The  prevalence  ratio
and its  95%  conﬁdence  interval  (95%CI)  were  used  to  verify  the  association  between  variables.
The Z  test  was  used  to  calculate  the  difference  between  proportions.
Results:  Considering  the  26  municipalities  of  the  Regional  Health  Superintendence  of  Alfenas,
there was  a  signiﬁcant  reduction  in  hospitalizations  for  community-acquired  pneumonia  in  chil-
dren younger  than  one  year  of  age,  with  prevalence  ratio  (PR)=0.81  (95%CI:  0.74--0.89;  p<0.05),
indicating  a  19%  lower  prevalence  of  hospitalization  for  community-acquired  pneumonia  in  the
post-vaccination  period.
Conclusions:  The  results  suggest  the  effectiveness  of  the  pneumococcal  10-valent  conjugatee  cases  of  community-acquired  pneumonia  in  children  younger  thanvaccine in  preventing  sever
one year  of  age.
©  2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY  license  (http://creativecommons.org/licenses/by/4.0/).
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Impacto  da  vacina  antipneumocócica  10-valente  na  reduc¸ão de  hospitalizac¸ão
por  pneumonia  adquirida  na  comunidade  em  crianc¸as
Resumo
Objetivo:  Descrever  e  analisar  a  ocorrência  de  internac¸ões  por  pneumonia  adquirida  na  comu-
nidade em  crianc¸as  antes  e  após  a  implantac¸ão,  no  Programa  Nacional  de  Imunizac¸ão,  da  vacina
pneumocócica  10-valente  (conjugada).
Métodos:  Trata-se  de  um  estudo  ecológico  que  incluiu  registros  de  crianc¸as  menores  de  um  ano,
vacinadas  e  não  vacinadas  com  a  vacina  antipneumocócica  10-valente  conjugada,  no  período
pré e  pós-inclusão  da  vacina  no  Programa  Nacional  de  Imunizac¸ão  na  área  de  abrangência  da
Superintendência  Regional  de  Saúde  de  Alfenas,  MG,  Brasil.  A  vacinac¸ão  foi  considerada  como
fator de  exposic¸ão  e  a  hospitalizac¸ão  por  pneumonia  adquirida  na  comunidade  como  desfecho,
com o  uso  de  dados  anuais  secundários  por  município.  Para  veriﬁcar  a  associac¸ão  entre  as
variáveis  foi  empregada  a  razão  de  prevalência  e  seu  intervalo  de  conﬁanc¸a  95%  (IC95%).  Para
o cálculo  de  diferenc¸a  entre  proporc¸ões  empregou-se  o  teste  Z.
Resultados:  Considerando  os  26  municípios  da  Superintendência  Regional  de  Saúde  de  Alfenas,
houve reduc¸ão  signiﬁcativa  do  número  de  hospitalizac¸ão  por  pneumonia  adquirida  na  comu-
nidade em  crianc¸as  abaixo  de  um  ano,  com  razão  de  prevalência  (RP)=0,81  (IC95%  0,74--0,89;
p<0,05),  o  que  indica  uma  prevalência  de  internac¸ão  por  pneumonia  adquirida  na  comunidade
19% menor  no  período  pós-vacinal.
Conclusões:  Os  resultados  sugerem  a  efetividade  da  vacina  pneumocócica  10-valente  (con-
jugada) na  prevenc¸ão  de  casos  graves  da  pneumonia  adquirida  na  comunidade  em  crianc¸as
menores de  um  ano.
©  2016  Sociedade  de  Pediatria  de  Sa˜o  Paulo.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um
artigo Open  Access  sob  uma  licenc¸a  CC  BY  (http://creativecommons.org/licenses/by/4.0/).
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Among  the  various  bacterial  etiologic  agents  involved  in
the  genesis  of  community-acquired  pneumonia  (CAP),  Strep-
tococcus  pneumoniae  is  the  main  cause  of  the  disease  in
children  and  adults.  Currently,  there  are  reports  of  91
serotypes1,2 associated  with  CAP  and  other  diseases.  How-
ever,  CAP  causes  greater  morbidity  and  its  occurrence  is
estimated  at  13.8  million  new  cases  worldwide  each  year.3,4
Between  6%  and  16%  of  CAP  cases  require  hospitaliza-
tion,  and  in  children  under  age  ﬁve,  the  disease,  particularly
of  bacterial  etiology,  accounts  for  20--40%  of  admissions
only  in  the  Americas.4 In  Brazil,  between  2004  and  2006,
pneumococcal  diseases  were  responsible  for  about  34,000
hospitalizations.
The  global  estimate  of  CAP  incidence  among  children
aged  1--5  years  in  developing  countries  is  0.29  episodes
per  child-year.  This  is  equivalent  to  an  annual  incidence
of  about  150  million  cases;  11--20%  of  these  cases  require
hospitalization.4 In  Brazil,  according  to  the  Hospital  Infor-
mation  System  (SIH-SUS),  from  January  2005  to  March  2006,
CAP  accounted  for  about  20%  of  the  hospitalizations  of  chil-
dren  under  age  ﬁve.5--7
Consensually,  preventive  measures  are  the  best  way  to
reduce  the  incidence  of  pneumococcal  disease  and  its  con-
sequences,  such  as  hospitalization  and  premature  death.5
Among  these  measures,  active  immunization  against  the
main  causative  agents,  particularly  certain  serotypes  of
Streptococcus  pneumoniae, has  proven  highly  efﬁcient  over
the  years  in  reducing  the  occurrence  of  severe  disease.5,6
In  Brazil,  with  the  incorporation  of  pneumococcal  vac-
cines,  particularly  10-valent,  since  2010,6,7 there  is  a
reduction  of  pneumococcal  diseases,  such  as  meningitis  and
B
t
a
tAP,8--10 in  children  under  two  years  of  age,  with  a  decline
n  the  number  of  hospitalizations,  malnutrition,  deaths,  and
arental  work  absenteeism,  as  well  as  cost  reduction,  among
thers.11,12
The  aim  of  the  present  paper  was  to  evaluate  the
mpact  of  10-valent  pneumococcal  conjugate  vaccine  (PCV-
0)  before  booster  shot  in  hospitalized  children  under  one
ear  of  age  with  CAP,  before  and  after  its  introduction  in
he  National  Immunization  Program  (PNI)  in  municipalities
elonging  to  the  Regional  Health  Superintendence  of  Alfenas
SRS/Alfenas,  MG,  Brazil).
ethod
his  is  an  ecological  study  including  records  of  children
nder  one  year  old  who  received  or  not  10-valent  pneumo-
occal  conjugate  vaccine  in  the  period  before  and  after  its
nclusion  in  the  PNI,  in  which  vaccination  was  considered
s  the  exposure  factor  and  CAP  hospitalization  as  the  end-
oint.  The  study  used  secondary  annual  data  by  municipality
o  calculate  vaccination  coverage  and  pneumonia  morbidity
ates  in  children  under  one  year  old  from  2007  to  2013.  Com-
arison  of  raw  numbers  (i.e.,  non-proportional  numbers)  of
AP  hospitalization  from  2007  to  2013  in  the  municipalities
elonging  to  SRS/Alfenas  was  performed.
We  assessed  records  of  children  up  to  one  year
ld,  living  in  26  municipalities  under  the  jurisdiction  of
RS/Alfenas----State  Department  of  Health  of  Minas  Gerais,
razil.  Data  were  collected  through  search  in  the  Informa-
ion  System  of  the  National  Immunization  Program  (SI-PNI)13
nd  Tabwin  database  available  in  the  Regulation  Cen-
er  of  SRS/Alfenas,  MG.  The  municipalities  belonging  to
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Table  1  Distribution  of  children  under  one  year  old  enrolled  in  the  26  municipalities  of  the  SRS/Alfenas,  MG;  in  pre-  and
post-vaccination  periods,  as  well  as  raw  and  mean  numbers  of  children  included  in  the  study  with  their  respective  losses  by
period.
Periods
Pre-vaccination  PCV-10  Introduction  Post-vaccination
2007  2008  2009  2010  2011  2012  2013
5969  5622  5628  5765  5669  5723  5667
Mean (A) -- Mean  (B)
5740 5765  5686
Records  (PNI)--SRS/Alfenas,  MG
2007  2008  2009  2010  2011  2012  2013
5107  5088  5080  5765  5215  5212  5213
Mean (C)  --  Mean  (D)
5091 --  5213
Losses  B−D  (%)
-- 8.3
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Figure  1  Number  of  hospitalizations  for  community-acquired
pneumonia  (CAP)  in  children  under  one  year  old  in  26  munic-
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RS/Alfenas  are:  Alfenas,  Alterosa,  Arceburgo,  Areado,  Ban-
eira  do  Sul,  Botelhos,  Cabo  Verde,  Campestre,  Campo  do
eio,  Campos  Gerais,  Carmo  do  Rio  Claro,  Carvalhópolis,
onceic¸ão  da  Aparecida,  Divisa  Nova,  Fama,  Guaranésia,
uaxupé,  Juruaia,  Machado,  Monte  Belo,  Muzambinho,  Nova
esende,  Paraguac¸u,  Poc¸o  Fundo,  São  Pedro  da  União,  and
errania.
During  the  period  mentioned  above,  the  entire  child  pop-
lation  was  included.  To  verify  the  association  between
ariables  (independent  and  response),  univariate  analyzes
ere  used,  with  measurement  of  the  relative  prevalence
RP)  ratio  and  its  respective  conﬁdence  interval  of  95%
95%CI)  as  association  estimators.  Subsequently,  a  multi-
ariate  logistic  regression  analysis  was  performed  and  all
xplanatory  variables  were  included  in  the  model  (num-
er  of  pediatric  CAP  hospitalizations,  adjusted  age,  sex,
unicipality  of  residence,  vaccination  status,  vaccination
overage).  Chi-square  test  was  used  for  difference  between
roportions  and  independent  samples  t  test  for  difference
etween  means.  For  all  analyzes,  a  5%  signiﬁcance  level  was
onsidered.  For  storage  and  analysis  of  data,  the  statisti-
al  software  SPSS  20.0® (IBM  SPSS  Statistics  for  Windows,
ersion  20.0,  Armonk,  NY,  USA)  was  used.
The  research  project  was  submitted  to  the  Institutional
eview  Board  of  the  Hospital  das  Clínicas  da  Faculdade  de
edicina  de  RibeirãoPreto,  USP,  and  was  approved  on  March
9,  2013  (CAAE  No:  12487113.5.0000.5440).
esults
his  study  aimed  to  evaluate  the  number  of  CAP  hospi-
alization  among  children  under  one  year  old,  so  before
he  booster  shot,  which  should  take  place  between  12  and
5  months,  and  vaccination  coverage,  which  occurred  in  the
eriod  that  comprised  the  pre-  (2007,  2008  and  2009)  and
ost-  (2011,  2012  and  2013)  introduction  of  PCV-10  in  the
mmunization  schedule  of  PNI  recommended  by  the  Ministry
f  Health.  Table  1  shows  the  number  of  children  in  each  of
he  years  in  the  pre-  and  post-vaccination  periods,  as  well
c
u
y
Tpalities  from  2007  to  2013.  Coordenadoria  de  Regulac¸ão  da
RS/Alfenas,  MG,  Brazil.
s  the  number  of  children  included  in  the  study.  One  should
ote  that,  in  the  period  prior  to  the  introduction  of  PCV-10,
he  losses  were  11.3%,  while  in  the  post-vaccine  period  they
ere  8.3%.  All  losses  were  due  to  inconsistent  records.
The  gross  number  of  the  male  and  female  children
ecords  between  2007  and  2009  was,  respectively,  2632  and
459  (p<0.05),  with  an  average  of  nine  months  (±1)  for
emales  and  10  months  (±1)  for  males  (p<0.05).  Considering
he  period  of  2011--2013,  there  were  2737  records  of  male
nd  2476  records  of  female  children  (p<0.05),  with  respec-
ive  averages  of  9.5±1  months  and  10±1.2  months.  There
as  a  signiﬁcant  difference  (p<0.05).
The  number  of  admissions  during  the  study  period  is
hown  in  Fig.  1.  As  it  can  be  noted,  the  number  of  CAP
dmissions  in  the  age  group  under  one  year  old  went  from
28  in  2007  to  624  in  2013.  There  were  5044  cases  of  CAP
dmissions  during  the  analysis  period.
In  March  2010,  there  was  the  10-valent  pneumococcal
onjugate  vaccine  introduction  in  the  vaccination  sched-
le  of  children  in  PNI.  Thus,  the  vaccination  coverage  that
ear  did  not  reach  the  95%  expected  coverage  (Table  2).
herefore,  vaccination  coverage  in  2010  was  not  evaluated
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Table  2  Distribution  of  10-valent  pneumococcal  conjugate  vaccine  coverage  in  children  in  2010,  2011,  2012,  and
2013--SRS/Alfenas,  MG,  Brazil.
Municipality 2010  2011  2012  2013
n  (%)  n  (%)  n  (%)  n  (%)
Alfenas  524  54.24  937  100.64  843  90.55  927  99.57
Alterosa 85  49.13  150  88.24  184  108.24  165  97.06
Arceburgo 23  22.55  76  73.08  117  112.50  99  95.19
Areado 94  45.41  171  97.16  169  96.02  199  113.07
Bandeira do  Sul  12  19.35  46  75.41  80  131.15  92  150.82
Botelhos 53  34.42 185  156.78  164  138.98  177  150.00
Cabo Verde 86  49.14 199  125.16 140  88.05  141  88.68
Campestre 115  49.36 215  101.90 184  87.20 235  111.37
C. do  Meio  52  45.22  142  112.70  161  127.78  121  96.03
C. Gerais  183  55.62  330  100.30  291  88.45  332  100.91
C. Rio  Claro  100  54.35  168  83.17  195  96.53  195  96.53
Carvalhópolis 23  46.00  43  107.50  43  107.50  42  105.00
Conc. Aparecida  74  57.81  145  131.82  144  130.91  103  93.64
Divisa Nova  60  71.43  84  123.53  82  120.59  77  113.24
Fama 5  20.00  20  86.96  24  104.35  31  134.78
Guaranésia 95  45.89  236  95.16  244  98.39  243  97.98
Guaxupé 387  61.23  645  105.56  708  115.88  633  103.60
Juruaia 73  89.02  90  84.11  128  119.63  131  122.43
Machado 285  58.52  519  102.57  463  91.50  461  91.11
Monte Belo  68  62.39  116  84.67  150  109.49  146  106.57
Muzambinho 120  50.21  264  112.34  243  103.40  253  107.66
Nova Resende  107  56.02  234  121.88  206  107.29  208  108.33
Paraguac¸u 107  47.35  254  102.01  271  108.84  245  98.39
Poc¸oFundo 103  65.19  157  95.15  176  106.67  182  110.30
S. P.  da  União  14  33.33  52  130.00  59  147.50  57  142.50
Serrania 30  30.30  104  101.96  107  104.90  93  91.18
Total 2878  52.72  5582  10
because  it  could  bias  the  analysis,  both  due  to  reduced  cov-
erage  and  the  possibility  of  delay  in  vaccine  seroconversion.
Fig.  2  shows  the  overall  number  of  CAP  admissions  in
periods  pre-  and  post-introduction  of  the  vaccine  in  PNI,
considering  all  the  municipalities  of  SRS/Alfenas.  When
considering  the  group  of  municipalities  that  comprises  the
2430
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Difference  –13.20%; 95% CI: –11.08% –15.31%; p<.05
Figure  2  Total  distribution  of  CAP  cases  in  children,  regis-
tered  in  the  municipalities  of  SRS  Alfenas,  MG,  Brazil  before
(2007--2009)  and  after  (2011--2013)  the  start  of  immunization
with 10-valent  pneumococcal  conjugate  vaccine.
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RS/Alfenas,  there  was  a  signiﬁcant  difference  of−13.20%
95%CI:−44.08%  to−15.31%;  p<0.05)  in  the  incidence  of
ediatric  CAP  hospitalizations  between  the  study  periods.
Multivariate  analysis  between  vaccination  status  and  the
ccurrence  of  CAP  hospitalization  in  each  of  the  26  munic-
palities,  adjusted  for  confounding  variables,  as  well  as  of
RS  as  a  whole,  can  be  seen  in  Table  3.
In  the  municipalities  of  Alfenas,  Areado,  Bandeira  do
ul,  Botelhos,  Cabo  Verde,  Campestre,  Carmo  do  Rio  Claro,
arvalhópolis,  Conceic¸ão  da  Aparecida,  Divisa  Nova,  Fama,
uzambinho,  Nova  Resende,  Paraguac¸u,  São  Pedro  da  União,
nd  Serrania  there  were  no  differences  in  CAP  preva-
ence  between  vaccinated  and  unvaccinated  children.  In
he  municipalities  of  Alterosa,  Arceburgo,  Campo  do  Meio,
ampos  Gerais,  Guaranésia,  Juruaia,  Machado,  Monte  Belo,
nd  Poc¸o  Fundo  there  was  a  decrease  in  CAP  hospitaliza-
ion  in  vaccinated  versus  unvaccinated  children,  as  shown
n  Fig.  3.  In  the  municipality  of  Guaxupé  there  was  a  signif-
cant  27%  increase  in  CAP  hospitalization  between  the  two
tudy  periods  (pre-  and  post-vaccination).  This  phenomenon
equires  further  clariﬁcation.  In  all  the  26  municipalities,
accination  may  have  been  responsible  for  a  19%  reduction
n  hospitalizations  due  to  CAP  cases  in  children  under  one
ear  old.  During  this  period,  there  was  no  mortality  from
AP  in  children  under  one  year  old  in  all  the  municipalities
f  the  SRS/Alfenas.
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Table  3  Analysis  of  the  association  between  vaccination  and  the  incidence  of  community-acquired  pneumonia  in  children  from
26 municipalities  of  the  SRS/Alfenas,  MG,  Brazil,  comparing  the  years  2007--2009  (before  pneumococcal  immunization)  with  the
years 2011--2013  (after  introduction  of  pneumococcal  vaccine).
Municipality  PR  95%CI  p-value
Alfenas  1.07  0.81--1.42  >0.05
Alterosa 0.36  0.13--0.95  <0.05a
Arceburgo  0.22  0.05--0.90  <0.05a
Areado  0.59  0.24--1.47  >0.05
B.do Sul 0.33  0.07--1.65  >0.05
Botelhos 1.02 0.44--2.38 >0.05
Cabo  Verde 1.26 0.79--1.99 >0.05
Campestre  0.71 0.35--1.41 >0.05
Campo  do  Meio  0.48  0.30--0.77  <0.05a
Campos  Gerais  0.59  0.41--0.87  <0.05a
Carmo  do  Rio  Claro  0.86  0.54--1.37  >0.05
Carvalhópolis  0.90  0.30--2.70  >0.05
Conceic¸ão da  Aparecida  0.53  0.21--1.35  >0.05
Divisa Nova  1.88  0.32--10.90  >0.05
Fama 0.41  0.04--4.20  >0.05
Guaranésia 0.23  0.15--0.36  <0.05a
Guaxupé  1.27  1.08--1.50  <0.05a
Juruaia  0.57  0.37--0.88  <0.05a
Machado  0.63  0.40--0.90  <0.05a
Monte  Belo  0.48  0.24--0.97  <0.05a
Muzambinho  0.88  0.41--1.91  >0.05
Nova Resende 0.72  0.44--1.19  >0.05
Paraguac¸u 1.04 0.54--1.89  >0.05
Poc¸o Fundo 0.37  0.15--0.89  <0.05a
São  Pedro  3.15  0.67--14.70  >0.05
Serrania 1.14  0.44--2.90  >0.05
SRS Alfenas  (Global) 0.81 0.74--0.89  <0.05a
PR, prevalence ratio; 95%CI, 95% conﬁdence interval.
a Signiﬁcant.
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Figure  3  Representation  of  the  prevalence  ratio  (PR)  speciﬁc  values  relating  to  CAP  hospitalization  in  children  up  to  one  year  old,
in each  of  the  26  municipalities,  and  considering  the  total  value  of  SRS-Alfenas,  MG,  Brazil,  after  the  introduction  of  the  PCV-10
vaccine. Columns  represent  the  values  of  prevalence  ratio  of  CAP  hospitalization  after  the  introduction  of  the  PCV-10  vaccine.
Horizontal line  represents  the  prevalence  ratio=1;  i.e.,  the  non-changing  line  in  the  prevalence  of  CAP  after  introduction  of  the
PCV-10 vaccine.
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Discussion
This  study  showed  a  19%  reduction  in  CAP  in  children  younger
than  one  year  between  2007--2009  and  2011--2013,  corre-
sponding  to  the  periods  before  and  after  the  introduction  of
the  immunization  schedule  of  PCV-10  in  2010  in  the  PNI,  in
26  municipalities  under  the  jurisdiction  of  SRS/Alfenas.
The  Ministry  of  Health  recommends  95%  as  the  ideal  rate
of  vaccination  coverage  able  to  give  efﬁciency  to  the  10-
valent  pneumococcal  vaccine  to  reduce  cases  of  CAP  and
other  invasive  pneumococcal  diseases.11,12,14 In  this  study,
the  average  coverage  rate  in  the  year  that  the  vaccine  was
introduced  was  only  52.7%;  however,  in  2011,  2012,  and
2013  the  rates  were  104.0%,  102.9%,  and  103.1%,  respec-
tively,  which  is  above  the  recommended.  It  is  expected,
therefore,  a  reduction  in  the  number  of  CAP  cases  and  its
consequences,  such  as  hospitalization  and  mortality,  which
was  actually  seen.  This  ﬁnding  is  similar  to  that  of  a  study  by
Afonso  et  al.15 reporting  a  reduction  of  pneumonia  cases  in
cities  where  the  coverage  was  over  95%,  unlike  the  cities
with  lower  coverage,  such  as  São  Paulo  (75%)  and  Porto
Alegre  (85%),  where  such  a  reduction  was  not  seen.  In  our
study,  as  shown  in  Table  2,  many  municipalities  showed  vac-
cine  coverage  above  100%.  This  probably  happened  due  to
two  important  facts.  The  ﬁrst  refers  to  the  intense  seasonal
migration  in  the  municipalities  during  the  coffee  harvest
period.  Rural  workers  and  their  families  who  seek  vaccina-
tion  centers  are  vaccinated  according  to  their  respective  age
groups.  The  second  fact  could  be  the  extensive  rural  area
that  many  municipalities  have.  Thus,  for  many  families,  the
distance  from  another  city  vaccination  center  is  shorter  than
that  of  their  own  cities.
In addition  to  the  aspects  directly  related  to  CAP  morbid-
ity  and  mortality,  with  impact  on  quality  of  life  of  children
and  their  parents,  there  is  the  economic  issue  associated
with  the  disease;  for  example,  the  cost  linked  to  its  man-
agement  (spending  on  antibiotics,  hospitalization,  clinical
tests,  parental  absence  from  work,  and  others).  Thus,  some
studies  have  shown  that  children  vaccination  against  pneu-
mococcus  is  cost-effective  from  the  perspective  of  society,
reduces  the  total  burden  of  pneumococcal  disease,  includ-
ing  CAP.  Martí  et  al.11 analyzed  the  cost-effectiveness  based
on  quality-adjusted  life  year  (QALY)  of  PCV-10  in  six  Latin
American  countries,  including  Brazil,  and  reported  that  the
incorporation  of  immunization  is  a  cost-effective  strategy  in
improving  health  standards  of  the  pediatric  population.
In  analyzing  the  periods  before  and  after  the  introduction
of  PCV-10  in  PNI,  as  shown  in  Fig.  1,  the  number  of  CAP  hos-
pitalizations  in  the  26  selected  municipalities  had  shown  a
decline  from  2009  (pre-vaccine  period),  a  fact  that  can  cer-
tainly  be  explained  by  better  sanitary  conditions,  increased
household  income,  as  well  as  gains  in  children  health  care
seen  in  recent  years  throughout  Brazil.  Thus,  vaccination
against  pneumococcus  brought  an  increase  to  the  decline
observed  in  its  post-introduction  period  since  2010.16--19
One  limitation  of  the  present  study  is  the  fact  that
it  is  an  ecological  study  in  which  the  observed  unit  is
not  the  individual,  but  a  group  of  people  representing  a
portion  of  the  population  that  is  under  the  jurisdiction  of
SRS/Alfenas  (children  under  one  year  old);  however,  we
used  ofﬁcial  sources  that  have  quality  control----Datasus,italization  for  CAP  423
I-PNI,  and  Tabwin----available  in  the  Regulation  Center  of
RS/Alfenas,  but  still  it  may  have  ﬂaws,  which  was  observed
n  the  loss  of  records  in  the  least  8.3%  of  cases  in  the
ost-vaccination  period.  Other  limiting  aspects  of  this  study
re  related  to  potential  confounding  factors,  such  as  the
mprovement  in  children’s  dietary  patterns,  observed  in  the
ast  decade,  contributing  to  a  decreased  incidence  of  severe
AP,  in  addition  to  vaccination,  presence  of  some  comorbidi-
ies,  and  differences  in  the  prevalence  of  PAC  between  male
nd  female.18,20 Finally,  another  limitation  is  the  fact  only
hildren  were  assessed  before  the  recommended  booster
hot  between  12  and  15  months.
In  the  PCV-10  post-advent  period,  there  was  a decreased
umber  of  PAC  in  children  under  12  months  old  in  the  region
f  SRS/Alfenas,  MG,  Brazil.  In  countries  where  pneumo-
occal  conjugate  and  even  polysaccharide  vaccines  were
stablished  and  maintained  with  high  vaccination  coverage,
he  reduction  of  invasive  pneumococcal  disease  is  signiﬁ-
ant;  the  same  result  was  found  in  this  study,  which  showed
 reduction  in  the  number  of  CAP  children  hospitalized  in
he  study  period.
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